UC Riverside-led national survey of MS specialists finds nearly 10% had been redeployed to the front lines of COVID-19 patient care

Even as vaccinations across the U.S. were ramping up due to the popularity and availability of the one-dose Johnson & Johnson vaccine, the CDC called a timeout due to reports of serious blood clots

PANDORA sequencing method developed by UC Riverside-led team can detect once-undetectable small RNAs

UC Riverside study identified toxic elements in pod atomizers

UC Riverside biomedical scientists were part of an international team that identified the coronavirus strain

Immunity generated by vaccination is better than immunity from an actual infection, says an expert

COVID-19 is far from beaten. Vaccines may not be the ultimate panacea to haul us out of the pandemic crisis. In the future, will outbreaks of SARS-CoV-2, the virus that causes COVID-19, arrive in waves every winter? Might COVID-19 never go away? Experts at the University of California, Riverside, weigh...

UC Riverside-led study examined the effects of the medication risperidone on brain metabolism in stuttering

Severe acne often leaves deep psychological scars, disproportionately affecting women and people with darker skin. Researchers say dermatological treatment isn't enough.

UC Riverside public health expert Richard Carpiano weighs in on ethical matters for vaccine distribution.

UC Riverside-led mouse study stresses MS treatment should be started early

UC Riverside epidemiologist answers this and other questions in Q&A

Dr. David Lo at the UC Riverside School of Medicine is an expert on vaccines

A UC Riverside-led study, funded by Merck, is set to find out

UC Riverside study examines molecular pathways that may instigate seizures in some multiple sclerosis patients

Phase 2 study investigates efficacy of the drug ecopipam developed by Emalex Biosciences Inc.

Host campus UC Riverside will be joined by UC Davis and UC Merced

Meeting virtually with people outside your household is safest, says UC Riverside epidemiologist

Neural crest study results could boost stem cell therapies

The news arrived Monday that the world has been awaiting since spring: a vaccine has been developed that shows a high degree of efficacy in late-stage trials: 90%. That puts it in the company of effective vaccines such as for measles, and well beyond what the medical community hoped for...